- Home
- ANL vs PRLD Comparison
ANL vs PRLD Comparison
Compare ANL & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | PRLD |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | Cayman Islands | United States |
| Employees | 123 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.0M | 69.1M |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANL | PRLD |
|---|---|---|
| Price | $1.85 | $1.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 1.3M | 532.8K |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 250.00 |
| 52 Week Low | $0.88 | $0.61 |
| 52 Week High | $2.75 | $4.22 |
Technical Indicators
Market Signals| Indicator | ANL | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 64.46 | 40.85 |
| Support Level | $1.48 | $2.05 |
| Resistance Level | $1.71 | $2.30 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 80.95 | 5.57 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.